Given the pathologic characterization of Alzheimer’s disease (AD) by amyloid-β (Aβ) plaques and neurofibrillary tangles, measurement of AD biomarkers amyloid beta (1–42 and 1–40) (Aβ42, Aβ40), total tau (t-tau), and phosphorylated tau at Thr181 (p-tau) in cerebrospinal fluid (CSF) is recommended for accurate AD diagnosis and research [1, 2]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.